Early production of HIV-1 neutralising antibodies in patients following highly active antiretroviral treatment (HAART) during primary HIV infection.

Claudia Barassi(Vita-Salute San Raffaele University), Lucia Lopalco(Vita-Salute San Raffaele University), Pierre Marraccini(Centre de Coopération Internationale en Recherche Agronomique pour le Développement), Antonio G. Siccardi(San Raffaele University of Rome), Brunella Capiluppi(Vita-Salute San Raffaele University), C. Bressi(Vita-Salute San Raffaele University), Giuseppe Tambussi(San Raffaele University of Rome), Donatella Ciuffreda(University of Milan), Claudia Pastori(Vita-Salute San Raffaele University), C. De Santis(University of Milan), Adriano Lazzarin(Vita-Salute San Raffaele University)
PubMed
June 8, 2000
Cited by 4

Related Papers

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression
|Nature Medicine|1997|635
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
|The Lancet|2009|620
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Control of HIV despite the Discontinuation of Antiretroviral Therapy
|New England Journal of Medicine|1999|328